PSEUDO-12 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Pseudo-12, and when can generic versions of Pseudo-12 launch?
Pseudo-12 is a drug marketed by Ucb Inc and is included in one NDA.
The generic ingredient in PSEUDO-12 is pseudoephedrine polistirex. There are forty-nine drug master file entries for this compound. Additional details are available on the pseudoephedrine polistirex profile page.
Summary for PSEUDO-12
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 26 |
Clinical Trials: | 97 |
Formulation / Manufacturing: | see details |
DailyMed Link: | PSEUDO-12 at DailyMed |
Recent Clinical Trials for PSEUDO-12
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Centre Hospitalier Universitaire Vaudois | Phase 2 |
Mclean Hospital | N/A |
Boston University Charles River Campus | N/A |
Anatomical Therapeutic Chemical (ATC) Classes for PSEUDO-12
US Patents and Regulatory Information for PSEUDO-12
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ucb Inc | PSEUDO-12 | pseudoephedrine polistirex | SUSPENSION, EXTENDED RELEASE;ORAL | 019401-001 | Jun 19, 1987 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |